Clinical Trial

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Study acronym: Adoring
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-13
notable Primary completion moved earlier: 2028-01 -> 2027-08 2026-08-13
minor Completion moved earlier: 2028-01 -> 2027-08 2026-08-13
Trial Details
NCT Number NCT07265479
Lead Sponsor Organon and Co
Conditions Atopic Dermatitis
Enrollment 187 participants
Start Date 2025-12-29
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-12